Market Tracker

07/22 5:16pm ET

ARIAD Pharmaceuticals Inc (NASDAQ:ARIA)

8.11
Delayed Data
As of Jul 22
 +0.13 / +1.63%
Today’s Change
4.37
Today|||52-Week Range
10.07
+29.76%
Year-to-Date
Cancer Stocks: 2 to Buy, 1 to Avoid
Jul 23 / MotleyFool.com - Paid Partner Content
Barbarian At The Gate: ARIAD Pharmaceuticals (ARIA)
Jul 20 / TheStreet.com - Paid Partner Content
Ariad Pharmaceuticals (ARIA) In Focus: Stock Jumps 8.2%
Jul 21 / Zacks.com - Paid Partner Content
Is Agenus or Ariad Pharmaceuticals the Better Long-Term Buy?
Jul 19 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close7.98
Today’s open7.97
Day’s range7.89 - 8.24
Volume6,136,555
Average volume (3 months)4,166,035
Market cap$1.6B
Dividend yield--
Data as of 3:59pm ET, 07/22/2016

Growth & Valuation

Earnings growth (last year)-41.38%
Earnings growth (this year)+41.46%
Earnings growth (next 5 years)+41.39%
Revenue growth (last year)+12.70%
P/E ratioNM
Price/Sales9.93
Price/Book--

Competitors

 Today’s
change
Today’s
% change
RLYPRelypsa Inc+0.12+0.38%
AXONAxovant Sciences Ltd+0.85+6.39%
MCRBSeres Therapeutics I...+0.81+2.41%
FPRXFive Prime Therapeut...+0.77+1.65%
Data as of 4:00pm ET, 07/22/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$118.8M
Annual profit (last year)-$231.2M
Net profit margin-194.57%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Paris Panayiotopoulos
Chief Financial Officer, Treasurer &
Executive VP
Manmeet Singh Soni
Corporate headquarters
Cambridge, Massachusetts

Forecasts